New hope for Tough-to-Treat gynecologic cancers
NCT ID NCT05691504
Summary
This early-stage study is testing a new combination of two drugs, pelcitoclax and cobimetinib, for women with ovarian or endometrial cancer that has returned after prior treatment. The main goals are to find the safest and most effective dose and to check for side effects. Researchers hope the drug combo will help shrink or stabilize tumors in patients who have limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-••••
-
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Cancer Institute Developmental Therapeutics Clinic
ACTIVE_NOT_RECRUITINGBethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
ACTIVE_NOT_RECRUITINGBethesda, Maryland, 20892, United States
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.